Global Patient-Derived Xenograft/PDX Model Market (2021 to 2026) - Rising Demand for Humanized PDX Models Presents Opportunities - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period.

Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.

The preclinical drug development segment accounted for the highest growth rate in the PDX models market, by application, during the forecast period

The PDX models market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment accounted for the highest growth rate in the PDX models market during the forecast period. This segment's high growth rate can be attributed to the rising number of clinical trials every year.

Contract research organizations segment accounted for the highest CAGR

Based on end users, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. During the forecast period contract research organizations accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.

Rat models segment accounted for the highest CAGR

Based on type, the PDX models market is segmented into mice models and rat models. The rat models segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. Moreover, the development of immunodeficient rats will further drive the usage of rat models in PDX model generation.

Respiratory tumor models segment accounted for the highest CAGR

Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The respiratory tumor models segment accounted for the highest growth rate during the forecast period. The key factor driving this segment's growth is the increasing incidence of lung cancers globally.

Asia Pacific: The fastest-growing country in the PDX models market

The PDX models market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the PDX models market in this region.

Market Dynamics

Drivers

• Growing Demand for Personalized Medicine
• Continuous Support for Cancer Research from the Public & Private Sectors
• Rising Pharma R&D

Restraints

• High Cost of Personalized PDX Models
• Stringent Guidelines for the Use of Animal Models in Cancer Research

Opportunities

• Rising Demand for Humanized PDX Models

Challenges

• Limitations of PDX Models

Companies Mentioned

• Abnova Corporation
• Aragen Life Sciences W.E.F
• Biocytogen
• Bioduro
• Champions Oncology
• Charles River Laboratories
• Envigo
• EPO Berlin-Buch Gmbh
• Explora Biolabs
• Genesis Biotechnology Group
• Hera Biolabs
• JSR Corporation
• Living Tumor Laboratory
• Oncodesign
• Pharmatest Services
• Shanghai Lide Biotech
• The Jackson Laboratory
• Urosphere
• Wuxi Apptec
• Xentech

For more information about this report visit https://www.researchandmarkets.com/r/295wpm